SITC 2020

Brentuximab vedotin| Research | Abstract 696

Brentuximab vedotin, a CD30 targeting antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo

Tisotumab vedotin | Research | Abstract 617

Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death

Ladiraztumab vedotin | Breast Cancer | Abstract 323

Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients

SEA-CD40 | Research | Abstract 438

Synergy between SEA-CD40 and chemotherapeutics drives curative anti-tumor activity in pre-clinical models

SEA-TGT | Research | Abstract 250

SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon FcγR engagement

Research | Research | Abstract 618

Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications